|
|
Tongjitang Chinese Medicines Revenues Lower in Q2
publication date: Aug 15, 2008
Tongjitang Chinese Medicines Company had the unfortunate responsibility of informing investors that, once again, its revenues for the quarter were lower than the year-earlier period. Trying to put a good face on the news, Tongjitang led its announcement by saying that Q2 revenues were up 13% from Q1, a hopeful sign. Still, the unavoidable fact remains that its Q2 sales, which came in at $17.4 million, were down 15% from 2007’s second quarter. The company’s problem remains that competitors are selling counterfeit versions of its flagship product, the TCM osteoporosis treatment Xianling Gubao. More details...
Stock Symbol: (NYSE: TCM)
|
ChinaBio® Events
ChinaBio® Partnering Forum 2012May 23-24, 2012 Suzhou, China >>More events...
Partner Events
 China Healthcare Investment Conference 2012March 13-15, 2012 Shanghai, China Shanghai CEO ConferenceMarch 28-29, 2012 Shanghai, China >>More details...
Other Events
China Pharmaceutical R&D SummitApril 23-26, 2012 Shanghai, China Biosimilars Asia 2012April 23-26, 2012 Shanghai, China Vaccines China 2012April 23-26, 2012 Shanghai, China
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|